Loading...
Docoh

Alnylam Pharmaceuticals (ALNY)

Filed: 6 Aug 20, 8:10am
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549
 

 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): August 6, 2020  (August 3, 2020)
 
Alnylam Pharmaceuticals, Inc.

Delaware
001-36407
77-0602661
(State or Other Juris-
diction of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)

675 West Kendall Street,
Henri A. Termeer Square
Cambridge, Massachusetts
02142
(Address of Principal Executive Offices)(Zip Code)

Registrant’s telephone number, including area code:  (617) 551-8200
 
Not applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class
 Trading Symbol(s)
 
Name of Each Exchange on Which Registered
Common Stock, $0.01 par value per share
 ALNY
 The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934(§240.12b-2 of this chapter).
 
Emerging growth company     ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐




Item 2.02.
Results of Operations and Financial Condition

On August 6, 2020, Alnylam Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2020. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.


Item 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)

On August 3, 2020, Barry E. Greene resigned from his position as the Company’s President, effective September 30, 2020, following seventeen years of service, initially as Chief Operating Officer, then as President and Chief Operating Officer, and most recently as President. In connection with his resignation, Mr. Greene and the Company will enter into a written agreement not later than September 30, 2020, which will contain the material terms under which Mr. Greene will provide consulting services to the Company, on an as needed basis, for a two-year period following the effective date of his resignation, as well as certain other terms relating to Mr. Greene’s departure.

(c)

Yvonne L. Greenstreet, MBChB, MBA, has been appointed to the position of President of the Company, effective October 1, 2020, in addition to her existing position as the Company’s Chief Operating Officer.

Dr. Greenstreet, 57, has served as the Company’s Chief Operating Officer since September 2016. Prior to joining the Company, Dr. Greenstreet most recently served as the founder and Managing Director of Highgate LLC, from January 2014 to August 2016. Prior to that time, Dr. Greenstreet served as the Senior Vice President and Head of Medicines Development at Pfizer Inc., a multinational pharmaceutical company, from December 2010 to November 2013. Prior to joining Pfizer, Dr. Greenstreet worked for 18 years at GlaxoSmithKline plc, or GSK, a multinational pharmaceutical, biologics, vaccines and consumer healthcare company, where she served in various positions, most recently as Senior Vice President and Chief of Strategy for Research and Development and as a member of GSK’s Product Management Board. Dr. Greenstreet currently serves on the Scientific Advisory Committee of the Bill and Melinda Gates Foundation and serves as a director of Pacira Pharmaceuticals and American Funds.



Item 7.01.
Regulation FD Disclosure

On August 6, 2020, the Company issued a press release announcing Mr. Greene’s resignation. A copy of this press release is furnished as Exhibit 99.2 to this Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.2 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01.
Financial Statements and Exhibits


     (d)     Exhibits

The following exhibits shall be deemed to be furnished, and not filed:

99.1
Press Release dated August 6, 2020.
  
99.2
Press Release dated August 6, 2020.
  
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: August 6, 2020ALNYLAM PHARMACEUTICALS, INC.
   
   
 By:/s/ Jeffrey V. Poulton
  Jeffrey V. Poulton
  Executive Vice President, Chief Financial
  Officer